Physician profile
Daniel Connors
NPI 1821357435
$4,169.46
in general payments reported to CMS, 2019-2025
13 companies · $90.53 in 2025
The $90.53 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $139 · 2021: $377 · 2022: $428 · 2023: $266 · 2024: $250 · 2025: $90.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $2,359.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $592.53 | 2019-2025 | Eylea, Eylea Hd |
| Alimera Sciences, INC. | $252.60 | 2020-2024 | Yutiq, Iluvien |
| Novartis Pharmaceuticals Corporation | $243.20 | 2019-2021 | |
| Eyepoint US, INC. | $196.83 | 2021-2022 | |
| Genentech USA, INC. | $159.21 | 2021-2024 | Vabysmo |
| Allergan, INC. | $118.37 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $73.77 | 2023-2025 | Syfovre |
| Abbvie INC. | $72.20 | 2022-2024 | Ozurdex |
| Alcon Vision LLC | $45.00 | 2019 | |
| Bausch & Lomb Americas INC. | $27.34 | 2022-2023 | Xipere |
| Ani Pharmaceuticals, INC. | $15.38 | 2025 | Yutiq |
| Genzyme Corporation | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Connors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.